Table 2

Characteristics of HLA-B7+ LRH-1+ patients who received a transplant from an LRH-1 donor

Patient (Pt)DiagnosisType of DLISample date, wk after DLIPresence of LRH-1–specific CD8+ T cellsLRH-1–specific CD8+ T cells (%) in sampleLRH-1–specific CD8+ T cells (%) after 2 weeks of culture
CML Therapeutic 25 1.6 12.8 
CML Therapeutic 11 0.1 0.7 
AML Preemptive 10 6.9 15.4 
AML Preemptive 18 − < 0.01 < 0.01 
B-ALL Preemptive 11 − < 0.01 < 0.01 
T-ALL Preemptive 19 − < 0.01 n.d. 
MM Preemptive 12 − < 0.01 < 0.01 
Patient (Pt)DiagnosisType of DLISample date, wk after DLIPresence of LRH-1–specific CD8+ T cellsLRH-1–specific CD8+ T cells (%) in sampleLRH-1–specific CD8+ T cells (%) after 2 weeks of culture
CML Therapeutic 25 1.6 12.8 
CML Therapeutic 11 0.1 0.7 
AML Preemptive 10 6.9 15.4 
AML Preemptive 18 − < 0.01 < 0.01 
B-ALL Preemptive 11 − < 0.01 < 0.01 
T-ALL Preemptive 19 − < 0.01 n.d. 
MM Preemptive 12 − < 0.01 < 0.01 

n.d. indicates not determined.

or Create an Account

Close Modal
Close Modal